Eikon Therapeutics, Inc. has set the price for its upsized initial public offering at $18.00 per share for 21,177,600 shares of common stock. The company has also granted the underwriting syndicate a 30-day option to purchase up to 3,176,640 additional shares at the same price.
The company estimates gross proceeds from the offering of approximately $381 million, before accounting for underwriting discounts, commissions and offering expenses. That estimate does not incorporate any proceeds that could result from exercise of the underwriters' option to buy additional shares.
Timing and listing
Eikon's common stock is slated to begin trading on the Nasdaq Global Select Market on February 5, 2026 under the ticker symbol "EIKN." The offering is expected to close on or about February 6, 2026, subject to customary closing conditions.
Underwriters and regulatory status
J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho are listed as joint book-running managers for the transaction. The Securities and Exchange Commission declared the company's Form S-1 registration statement effective on January 30, 2026.
Company profile
Eikon describes itself as a late-stage clinical biopharmaceutical company concentrating on developing medicines for serious unmet medical needs. The company has identified oncology as its initial therapeutic focus, advancing drug candidates aimed at high unmet need in large indications. Eikon also operates a technology platform that the company says includes a proprietary single molecule tracking system used in its therapeutic discovery and development efforts.
Context and next steps
The pricing and related disclosures are drawn from a company press release. Investors and market participants will watch for the closing, expected on or about February 6, 2026, and for any exercise of the underwriters' 30-day overallotment option, which would alter the final proceeds to the company.